header logo image


Page 772«..1020..771772773774..780790..»

Biobanking Equipment Market To Grow at a Stayed CAGR with Huge Profits by 2029 | Thermo Fisher Scientific Inc, BioLife Solutions Inc, Beckman Coulter…

December 13th, 2019 8:49 pm

New York City, NY: Dec 14, 2019 Published via (Wired Release) A recent business intelligence report out by Marketresearch.biz with the title Global Biobanking Equipment Market Extensive Study and Forecast 2019-2028 offers new insights and explanation on the market and help you to improve and enamel your business strategies. Biobanking Equipment market has abilities to rise as the most remarkable market globally as it has carried a crucial role in establishing a progressive impression on the universal economy.

The Global Biobanking Equipment Market report analysis comprises an extensive summary of the market that offers in-depth knowledge of various distinct segmentations. Biobanking Equipment Market Research Report gives a detailed analysis depend on the comprehensive research of the complete market, especially on questions that outskirt on the market size, growth landscape, potential opportunities, operation scenario, trend study, and competitive analysis of Biobanking Equipment Market. The data contains the company profile, Y-O-Y turnover, product type and services, income generation, which offers direction to businesses to take crucial steps.

The main aim of the Biobanking Equipment report is to assist the user to understand the market based on definition, distribution, industry potential, recent trends, and market challenges industry faces. Detailed researches were done while structuring the report. The Biobanking Equipment market readers will find this report very easy to understand and beneficial. The prospects and information presented in the report using Biobanking Equipment figures, bar-graphs, pie charts, and other visual representations. This enhances the Biobanking Equipment market pictorial representation and also get the benefit of getting the industry facts easily.

The Biobanking Equipment Market was valued at USD XX.XX Mn in 2020 and is projected to reach a value of USD XX.XX Mn by 2029 with an estimated CAGR value of X.X%.

Note: The above values marked with XX.XX is confidential information. To know the exact data and values, fill your information so that our sales team can get in touch with you.

For Better Understanding, Request A Free Pdf Sample Report Of Biobanking Equipment Market Here@ https://marketresearch.biz/report/biobanking-equipment-market/request-sample

Biobanking Equipment Market scope

A basic synopsis of the competitive landscape

A short summary of the market segmentation and sub-segments

An exhaustive breakdown of the regional expanse

A generic outlook of the competitive landscape

The report serves a thorough study of the competitive territory of this vertical.

The study includes details related to each industry participants particular market share, the area served, manufacturing data and more.

Information related to the producers product portfolio, product characteristics, and relevant product applications has been presented in the report.

The report includes companies profiles in association with the respect of the fact to their gross margins and price models

Biobanking Equipment delivers pinpoint study of distinct competition dynamics and place you ahead of Biobanking Equipment competitors such as BioCision, Thermo Fisher Scientific Inc, VWR International, Taylor-Wharton International LLC, BioLife Solutions Inc, Tecan Trading AG, Panasonic Biomedical Sales Europe BV, Beckman Coulter Inc, Promega Corporation, LLC, LLC and Tecan Group Ltd

A brief outline of the segmentation

The Biobanking Equipment Market report demonstrate the segmentation of this vertical with utmost precision.

Information with reference to Biobanking Equipment industry share assemble by each product segment, along with their market value, have been served in the report.

Data related to production growth has also been offered in the report.

With respect to the application spectrum, the analysis comprises details regarding market share, amassed by every application segment.

Further, the analysis emphasizes data related to the product consumption of each application, together with the growth rate to be estimated for by each application segment over the projected period.

Segmentation by product type: Equipment, Refrigerators and Freezers, Liquid Nitrogen Supply Tanks, Cryogenic Storage Systems, Media, Optimized Pre-Formulated Media, Non-Optimized Isotonic Formulation Media, Consumables, Others. Segmentation by sample type: Human Tissue and Tumor Cells, Bio-fluids, Stem Cells, Umbilical Cord, DNA/RNA. Segmentation by end user: Hospitals, Research Organizations, Blood Banks, Others (DNA Banks and Cell and Tissue Banks)

Any Query? Fill Free To Inquire Here: https://marketresearch.biz/report/biobanking-equipment-market/#inquiry

Biobanking Equipment Market: Regional analysis includes:

Asia-Pacific (Japan, Philippines, Korea, Vietnam, China, Malaysia, Thailand, India, Indonesia, and Australia)

Europe (Russia UK, Italy, Turkey, Germany, France, etc.)

North America (United States, Mexico, and Canada.)

South America (Brazil, Argentina, Chile etc.)

The Middle East and Africa (GCC Countries, Dubai, Iran and Egypt)

An all-inclusive portfolio of the geographical terrain

The research report comprehensively segments the geographical landscape of this industry. As per the report, the Biobanking Equipment Market has established its appearance across the distincr regions such as United States, Japan, China, Europe, Southeast Asia & India.

The report consist insights relating to the industry share obtain by each region. Moreover, data regarding growth opportunities for the Biobanking Equipment Market across every comprehensive region is provided within the report.

The predicted growth rate recorded by each region over the forecast years has been precisely mention within the research report.

Some of the Major Highlights of TOC covers:

Biobanking Equipment Market Regional Analysis

Biobanking Equipment Production by Regions

Worldwide Production by Regions

Biobanking Equipment Market Global Revenue by Regions

Consumption by Regions

Biobanking Equipment Market Segmentation Study (by Type)

Worldwide Biobanking Equipment Production by Type

Global Revenue by Type

Global Share by Type

Biobanking Equipment Market Price by Type

Biobanking Equipment Market Segmentation Study (by Application)

Global Biobanking Equipment Consumption by Application

Global Market Share by Application

Global Revenue by Application

Biobanking Equipment Market Price by Application

Biobanking Equipment Major Manufacturers Study

Production Sites and Region Served

Product Introduction, Application and Stipulation

Biobanking Equipment Production, Ex-factory Price, Revenue, and Gross Margin

Vital Business and Markets Served

Browse More Insight Of This Biobanking Equipment Market Research Report Enabled with Respective Tables and Figures at: https://marketresearch.biz/report/biobanking-equipment-market/

Thanks for going through this article, you can also get separate chapter wise section or region wise section report. Also, if you have any special/particular requirements, please let us know and we will serve you the report accordingly.

Contact Us:

Mr. Benni Johnson

Prudour Pvt. Ltd.

420 Lexington Avenue,

Suite 300 New York City, NY 10170,

United States

Tel: + 1-347-826-1876

Email ID: inquiry@marketresearch.biz

Website: https://marketresearch.biz/

Read the original:
Biobanking Equipment Market To Grow at a Stayed CAGR with Huge Profits by 2029 | Thermo Fisher Scientific Inc, BioLife Solutions Inc, Beckman Coulter...

Read More...

Autologous Stem Cell and Non-Stem Cell Based Therapies Market share, size, opportunities, producers, growth factors by 2026 – Health Opinion

December 13th, 2019 8:49 pm

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report 2018-2026includes a comprehensive analysis of the present Market. The report starts with the basic Autologous Stem Cell and Non-Stem Cell Based Therapies industry overview and then goes into each and every detail.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Report contains in depth information major manufacturers, opportunities, challenges, and industry trends and their impact on the market forecast. Autologous Stem Cell and Non-Stem Cell Based Therapies also provides data about the company and its operations. This report also provides information on the Pricing Strategy, Brand Strategy, Target Client, Distributors/Traders List offered by the company.

Description:

Autologous stem-cell transplantation (also known as autogeneic, autogenic, or autogenous stem-cell transplantation or auto-SCT) is the autologous transplantation of stem cellswhich is, transplantation in which the undifferentiated cells or stem cells (cells from which other types of cells develop) are taken from a person, accumulated, and given back to the same person later. Even though it is most often executed by means of hematopoietic stem cells (antecedent of cells that forms blood) in hematopoietic stem cell transplantation, in some cases cardiac cells are used productively to fix the damages due to heart attacks. Stem cell transplantation can be of two types Autologous stem-cell transplantation and allogenic stem cell transplantation. In the later, the recipient and the donor of stem cells are dissimilar people. In a good number of allogeneic transplants, the stem cells are taken from a donor whose cell type matches closely with the patients cell type.

Autologous Stem Cell and Non-Stem Cell Based Therapies Market competition by top manufacturers/players, with Autologous Stem Cell and Non-Stem Cell Based Therapies sales volume, Price (USD/Unit), Revenue (Million USD) and Market Share for each manufacturer/player; the top players including: NeoStem, Inc., Aastrom Biosciences, Fibrocell Science, Inc., Genzyme Corporation, BrainStorm Cell Therapeutics, Regeneus Ltd., and Dendreon Corporation.

Get Free Sample Copy Of This Report @ https://www.coherentmarketinsights.com/insight/request-sample/523

Important Features that are under offer & key highlights of the report:

What all regional segmentation covered? Can the specific country of interest be added?Currently, the research report gives special attention and focus on the following regions:North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain etc), South America (Brazil, Argentina etc) & Middle East & Africa (Saudi Arabia, South Africa etc)** One country of specific interest can be included at no added cost. For inclusion of more regional segment quote may vary.

What all companies are currently profiled in the report?The report Contain the Major Key Players currently profiled in this market.** List of companies mentioned may vary in the final report subject to Name Change / Merger etc.

Can we add or profiled new company as per our need?Yes, we can add or profile new company as per client need in the report. Final confirmation to be provided by the research team depending upon the difficulty of the survey.** Data availability will be confirmed by research in case of a privately held company. Up to 3 players can be added at no added cost.

Can the inclusion of additional Segmentation / Market breakdown is possible?Yes, the inclusion of additional segmentation / Market breakdown is possible to subject to data availability and difficulty of the survey. However, a detailed requirement needs to be shared with our research before giving final confirmation to the client.** Depending upon the requirement the deliverable time and quote will vary.

Get PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/523

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Dynamics in the world mainly, the worldwide 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market is analyzed across major global regions. CMI also provides customized specific regional and country-level reports for the following areas:

Region Segmentation:

North America (USA, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Columbia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Further in the report, the Autologous Stem Cell and Non-Stem Cell Based Therapies market is examined for Sales, Revenue, Price and Gross Margin. These points are analyzed for companies, types, and regions. In continuation with this data, the sale price is for various types, applications and region is also included. The Autologous Stem Cell and Non-Stem Cell Based Therapies industry consumption for major regions is given. Additionally, type wise and application wise figures are also provided in this report.

Quick Buy This Premium Report From Here: https://www.coherentmarketinsights.com/insight/buy-now/523

In this study, the years considered to estimate the market size of 2018-2026 Autologous Stem Cell and Non-Stem Cell Based Therapies Market are as follows:History Year: 2015-2017Base Year: 2017Estimated Year: 2018Forecast Year 2018 to 2026

See original here:
Autologous Stem Cell and Non-Stem Cell Based Therapies Market share, size, opportunities, producers, growth factors by 2026 - Health Opinion

Read More...

Why you need to know about telomeres – MultiBriefs Exclusive

December 13th, 2019 8:47 pm

Many of us know that long-term stress can affect our health, but did you know that it can also impact aging and longevity?

Welcome to the world of telomeres.

According to an article by The American Institute of Stress, Telomeres are little caps at the end of chromosomes that prevent loss or injury to genetic information during cell division. Each time a cell divides, part of the telomere is lost and it becomes shorter. When a telomere eventually disappears because of repeated cell divisions, chromosomal damage prevents the cell from accurately reproducing itself. This shortening and eventual erosion of telomeres are prevented or reduced by telomerase, an enzyme in cells that preserves their length. Many believe that telomere destruction and reconstruction is related to the balance between aging and cancer and explains why cancer is more common in the elderly.

In addition to cancer, shorter telomeres have also recently been associated with a whole host of other diseases, including cardiovascular disease, osteoporosis and diabetes.

I first learned about telomeres in 2016, when I worked for a human potential physician that specialized in optimizing health through lifestyle changes. He was one of the first physicians in the country that built his practice around the awareness that lifestyle and behaviors impact ones genetics.

My former boss told me that his high stress levels during his medical training had severely shortened his telomeres and that he was working hard to reverse that by optimizing his own health as well as that of his patients. Not only was I excited to learn about this, but it was also inspiring to learn that there were ways to undo previous damage.

The foundation of his approach was based on measuring stress levels and then teaching people through biofeedback to regulate breathing and heart rate. He then added personalized recommendations based on individual genetics for additional stress-reducing and health-enhancing lifestyle changes, including diet, exercise, meditation, sound therapy, acupuncture, etc.

My former boss was in good company. A number of researchers and physicians were studying how lifestyle changes could reverse telomere shortening. One of the first studies was published in 2013 by Dean Ornish, a physician, best-selling author and head of the Preventative Medicine Research Institute at the University of California in San Francisco.

There is now a lot more information available versus 2013. A best-selling book, The Telomere Effect: A Revolutionary Approach to Living Younger, Healthier, Longer, was published in 2017 and was co-authored by Dr. Elizabeth Blackburn, who originally discovered the role of telomeres on aging, and psychologist Dr. Elissa Epel. Heres a wonderful passage from the book:

To an extent that has surprised us and the rest of the scientific community, telomeres do not simply carry out the commands issued by your genetic code. Your telomeres, it turns out, are listening to you. They absorb the instructions you give them. The way you live can, in effect, tell your telomeres to speed up the process of cellular aging. But it can also do the opposite.

The book is full of helpful information. For optimal health, the authors recommend a plant-based diet of nutrient-rich foods that are high in antioxidants. In addition, they also recommend focus, mindfulness and meditation as stated here:

One study has found that people who tend to focus their minds more on what they are currently doing have longer telomeres than people whose minds tend to wander more. Other studies find that taking a class that offers training in mindfulness or meditation is linked to improved telomere maintenance.

The benefits of making healthy lifestyle choices are well-known. However, knowing that you can greatly increase your chances of living longer and becoming healthier in the process because youre changing your genetic expression is pretty amazing.

Since were almost at the end of 2019 and about to begin a new year, this might be a perfect time to implement some new lifestyle choices, especially now that you know that your telomeres are listening.

See more here:
Why you need to know about telomeres - MultiBriefs Exclusive

Read More...

Cannadabis: tissue culture and the future of cannabis cultivation – Health Europa

December 13th, 2019 8:47 pm

Cannadabis Medical INC they intend to create a healthier and more consciously aware environment for the cannabis industry, and its participants, to thrive in.

Did you know that Cannadabis are Partners with us? Discover their featured Partner Page about a healthier, environmentally conscious cannabis industry.

The company is a family run company that was founded in Humboldt, Saskatchewan.

Founders, Alexander Calkins, BSc and Markus Li, P.Chem, MBA, are personally and emotionally invested in the science of cannabis. They each have family members that are dealing with incurable ailments, complications of which can often become fatal.

In the search for natural products that will improve the quality and longevity of life, the founders began working with cannabis. While there is no likelihood of a cure, the symptom management has been very positive for their family members. After witnessing the improvements, Cannadabis founders Calkins and Li, have dedicated themselves to furthering the medical cannabis movement.

Calkins and Li both have backgrounds in technical science and business. They are experienced cultivators and have a strong understanding of energy systems (practically essential for a power-hungry industry), process automation, and large-scale development.

Their familiarity with multi-industry supply chains has leveraged them into a cannabis development that is simultaneously high-tech, old school, and simple.

Through observation of established global industries, Cannadabis is building a multi-faceted business model based on sustainable practices, a strong genetics portfolio, disruptive technologies, hyper-specialisation, and holistic production.

Driven by a passion to help others in need, Calkins and Li took it upon themselves to bring their methods and expertise to the cannabis world. They recognise and praise the patient independence that medical cannabis can provide.

While they champion the practice of homegrown medicine, they have obligated themselves to providing the safest and highest quality medical products to those who are unable to grow for themselves.

Once Cannadabis has perfected its organic growing system, they will build and operate all future cultivation sites according to (EU) GMP and ISO:9001 2015 standards. By adopting these standards, Cannadabis will have the ability to share their cultivated passion with the world.

To meet the sanitary requirements of GMP and processing limitations of an organic certification, Cannadabis will be using a combination of reactive oxygen, electrolysed water, and radio frequency pasteurisation technologies.

Being a medically focused company, Cannadabis recognises that medical consumers have turned to cannabis because they are looking for natural remedies and are becoming increasingly weary of synthetic medicines.

For Cannadabis, producing medical cannabis using anything other than organic methods would transgress the fundamental sentiment that drives the global, medical movement. That is why Cannadabis is committed to attaining internationally recognised organic certifications on expanded production.

The companys flagship facility is intended to be an R&D focused proving ground for state-of-the-art organic cultivation methods. Cannadabis currently uses an inhouse blended soil, made only with organic ingredients. Their living soil has the benefit of creating terpene dense medicine, reducing cost, and simplifying processes.

With all the nutrients available in the soil, the plants require only water from transplant to harvest. Additionally, the growing medium and all organic waste can be recycled through vermicomposting, further reducing long term costs and needless waste.

Cannadabis will adopt various technologies to reduce energy demand and environmental impact. In addition to using LEDs and solar panels, Cannadabis will use combined heat and power (CHP) (or cooling combined heat power (CCHP)) at their cultivation facilities. CHP units burn natural gas to generate power and the waste heat is used to heat water and the workspace. CHPs are quickly becoming popular for reducing carbon emissions. In certain applications, CHPs reduce carbon emissions by 30-40%, compared to when power is taken from the grid.

Cannadabis will also divert the combustion CO2 into the growing space. CO2 supplementing supercharges growth naturally, increasing yield by 30-60%, and further reducing the carbon emissions from power generation. In the future, expanded cultivations may integrate pyrolysis of waste biomass, which will supply power and nutrient dense biochar to the living soil.

Cannadabis is aspiring to build a unique indoor growing system that uses a combination of solar power, water recycling, CHP (CCHP), pyrolysis, CO2 supplementation and vermicompost to create a no waste, carbon neutral, minimal input, self-regenerating nutrient, off grid, medical grade, organic, indoor cultivation.

Calkins and Li hope to validate the system and then apply the techniques to food cultivation; this type of system could revolutionise the food production in remote locations, like the northern territories, Alaska and would deliver food supply independence to small communities or reservations. Where biomass is abundant, this system would produce all year, requires only labour as inputs, self-generate power off-grid, and would also be carbon negative over extended time frames.

On their path to improving growing efficiency, Cannadabis has developed proprietary tissue culture methods specifically for cannabis. These methods are based upon the decades old horticultural practice that has been essential for the sterile propagation of ornamental and food cultivars; non seed propagation.

Developing an inhouse tissue culture system has the following benefits:1

Tissue culture revitalises cultivars and produces more vigorous plants Regeneration from meristem rids systemic disease; Propagation is significantly more efficient; Starting with 100 traditional cuttings; able to produce 70,000 annual clones; Start with 200 tissue culture vials; produce 2 million annual clones; Uses 1/10 the space of traditional cloning; Per square foot, tissue culturing is >100x more efficient; and Two million annual clones could be produced in less than 3000 square feet.

1000 mother cultivars could be stored inside a refrigerator with no care or maintenance for months, sometimes over a year; and Pest invasion would not affect mother cultures (many cultivators without tissue culture have lost their entire genetic inventory to viruses and fungi).

Cannadabis will be sharing its tissue culture methods with industry members who want to stay one step ahead of pests and systemic disease. Following more development, they will also be making their organic formulations available.

Having collected and grown a large variety of cultivars, both through seed and clone, the Cannadabis founders have noticed a distinct lack of quality in the genetics market. Over time, most of the popular cultivars of the world have been slowly degraded by deleterious breeding practices like selfing (feminising), backcrossing, and poor mother plant maintenance which promotes genetic drift.

The current genetics market is rife with breeders that take prized clones and spray them with colloidal silver to produce feminised seed, or they are crossed onto their own cultivars and backcrossed until stable seed is produced.

While these name sake creations may capture some of the qualities of the original strain, like trichome density or terpene profile, the progeny will lack the genetic diversity needed to produce healthy plants. Often, these weakened strains have reduced yield, potency, and pest resistance. In response to this, Cannadabis has focused on breeding their own high yield, high potency, flavour dense strains for commercial production.

The Cannadabis team is eager to unveil their propriety strains to the domestic and international medical markets. Over the past few years, the founders have started breeding their own cultivars. Currently, the team has focused on a selection of stabilised true breeds (landrace or F5+) for creating original F1 breeds.

Where the F1 generation is created by breeding male and female plants that are distinctly unique from each other; traditional F1s are created by crossing landrace indicas with landrace sativas.

These crosses need to be done with highly stable and uniquely different parents to produce a true F1 progeny that has abundant hybrid vigour. A plant with true hybrid vigour will typically have higher potency, increased pest resistance, and a higher yield than both parent plants; on average yield can be as high as 20% more than either parent.

Due to the nature of the F1 progeny, very few breeders release true F1 seeds. If highly stable progenitors are not used, the seedstock will be incredibly variable, which is unfavourable for consumers, who typically want consistency in their seed. However, as commercial cultivators, Cannadabis believes that F1 hybrids are essential for producing at large scale. The breeding and phenotyping can be a long and arduous process, the fruits of labour are not without commercial benefit.

Building upon the tissue culture and breeding practices, Cannadabis is quickly developing polyploidisation methods for creating ultra-premium cultivars. Polyploidisation is another common horticultural practice that Cannadabis expects to apply to their cannabis breeding projects.

Polyploidisation is a naturally occurring mechanism where the chromosomes of the plant cells become doubled within the same nucleus. This mechanism has played a significant role in speciation of crops, occurring frequently in nature, usually due to stress response.

In the 100 years since scientists discovered polyploidy, there has been rapid development of polyploid breeds. It is estimated that up to 80% of all flowering plants have polyploid varieties.2 Common polyploid cultivars includes wheat, coffee, banana, strawberry, potato, etc.

Polyploidy has been researched since the early 1900s. Scientists first used heat and electrical stress to induce those mechanisms. Today polyploidy is more commonly, and consistently, induced with radiation and stressing chemicals. Interestingly, induced polyploidy is explicitly exempt by most organic certification bodies. These types of breeds typically do not fall under genetically modified until foreign, non-similar species, DNA is introduced to the plant cell.

These polyploids are called autopolyploid (same species), and plants made with dissimilar species are called allopolyploids. Cannadabis will also be exploring organic permitted cell fusion; this would allow breeding with two male plants, or two female plants.

In the past, the following horticulture benefits have been derived from polyploidy and cell fusion, which Cannadabis hopes to similarly apply to the cannabis plant:3

The same can apply to cannabis. Strains can be developed that would never seed regardless of direct pollination; massive utility available to outdoor or indoor cultivators with seeding problems.

Cannadabis hopes to release their first polyploid strains in late 2020.

Cannadabis has begun manufacturing premade tissue culture mediums and are currently distributing them to Western Canadian horticulture stores and Amazon Marketplace; the mediums are a standard blend that works on 95%+ of the founders cultivars. The founders tissue culture experience is being provided to the public in both consumer and commercial grade products.

The introductory products show unfamiliar users how to do tissue culture at home, using proven methods that do not require expensive laboratory equipment. Besides what comes in the starter kit, the everyday home grower will usually have all the remaining materials at home. Commercial format mediums are intended for growers that want the best value and space savings.

Cultivators of any background can find information or help on tissue culture through the Cannadabis homepage. They are posting helpful videos and literature on cannabis tissue culture and hope to share the benefits with every grower. All horticulturalists, cannabis or not, can benefit from having their cloning area be 100x more efficient, through stackable containers. Furthermore, their mother plants can easily be maintained with minimal care. 100-1000 mother cultures can be stored within a refrigerator for 4-8 months, no adding nutrient or water. For larger cultivators, Cannadabis provides PGR matrices to more easily troubleshoot difficult cultivars. They also will custom blend and sterilise mediums to customer preference.

Cannadabis has begun developing an automated cell culture process for mass propagation of cultivars. The economies of scale of which are expected to change the supply chain of the entire cannabis industry. Automated cell culturing will provide starting materials to the industry at a fraction of the cost of inhouse cloning. Clones produced through cell culturing will also have the benefit of being totally sterile and free from disease.

Cannadabis has been offered an NRC-IRAP grant for initial developments of the process and are in early negotiations with a Canadian cannabis company to commercialise. The founders are expecting to file patents, mid 2020, and begin construction of a commercial scale process by mid-2021. Cannadabis anticipates that a 5000 sq ft facility will produce 5+ million clones annually, with minimal labour.

The project is looking to possibly incorporate the production of artificial seeds, which would simplify transportation and ease of storage for cultivators. They will also be developing cryogenic preservation methods. Cultivators around the world are encouraged to reach out to Cannadabis if they are looking to simplify their process, access cell culture benefits, and maximise growing space.

Working with Cannadabis cultured clones will be the most affordable, safe, and efficient way of acquiring starting material. Their services would include meristem culturing to remove systemic disease, and long-term storage of genetic inventory. Partners who end up with a pest could rest easy knowing their mother cultures will be perfectly preserved in tissue culture, and fifty thousand clones for the next crop are still on the way.

Cannadabis Medical and Delta 9 Cannabis have teamed up to provide an affordable, turnkey, tissue culture laboratory, complete with operating procedures, equipment, and cannabis medium recipes.

The two companies have co developed this system for their own commercial use and have recently made the system available for other cultivators. Both companies have recognised that the cannabis industry is still reliant on black market methods of propagation, and as a result, there have been countless incidents of crop and genetic loss in the legal industry; many of the stories circulating are understandably refuted by the companies experiencing such loss.

Rather than ignore the inevitable pest problems, the two companies are going toe to toe with mother nature, developing half century old technology and making it specifically for cannabis. Hopefully delivering the same modicum of control to the rest of the industry; cultivators slow to develop tissue culture science may soon find their genetics and crop totally destroyed by a single, often microscopic pest. On a commercial scale, these pests become essentially impossible to remove without the use of tissue culture.

With feet rooted in genuine care, Cannadabis and Delta 9 are prepared and excited to deliver a tissue culturing system to the global cannabis industry. They recognise the value and utility available to growers, and they also recognise that learning tissue culturing can feel out of reach for cultivators with no prior knowledge, or excess funding to hire an inhouse specialist.

Instead of missing out or paying specialists, cultivators can rely on Cannadabis and Delta 9 to deliver a ready to use laboratory, the development of which was based on maximising value for the growers.

The laboratory comes with only bare essentials and extensive, yet simple, operating procedures. Training materials will detail cannabis specific mediums, sanitation protocols, along with troubleshooting methods for finicky cultivars; an inexperienced grower will be comfortably blending and using mediums on the same day of commissioning. The whole system, equipment and all, will be much more affordable than hiring a tissue culture specialist.

Over the next three years, Cannadabis will be working to establish an expanded cultivation with the hope of supplying medical, organic, indoor grown cannabis to domestic and international markets.

They will also pioneer an original cell culture process that expects to be the most affordable source for starting materials in the world; Cannadabis is especially excited to deliver their polyploid cultivars as starting materials to industry members.

Cannadabis would like to offer an open invitation to all scientists, entrepreneurs, and industry professionals for collaboration. We are actively seeking partners who share a similar vision for the cannabis industry. Any professionals who are driven by a sense of genuine care and have a passion for cannabis medicine are encouraged to reach out.

References

1 hempindustrydaily.com/hemp-cultivators-tissue-culture-increase-propagation-preserve-genetics/2 Meyers, L. A., and Levin, D. A. (2006). On the abundance of polyploids in flowering plants. Evolution 60, 11981206. doi: 10.1111/j.0014 3820.2006.tb01198.x3 http://www.slideshare.net/ranganihennayaka/plant-polyploids4 http://www.frontiersin.org/articles/10.3389/fpls.2019.00476/full5 plantbreeding.coe.uga.edu/index.php?title=5._Polyploidy

Alexander CalkinsCEOCANNADABIS Medical INC+1 306 552 4242alexander@cannadabismedical.caTweet @cannadabiscannadabismedical.ca

This article will appear in the first issue ofMedical Cannabis Networkwhich will be out in January.Clickhereto subscribe.

Follow this link:
Cannadabis: tissue culture and the future of cannabis cultivation - Health Europa

Read More...

Keeping Your Childs Baby Teeth Could Save Their Life In The Future – BabyGaga

December 13th, 2019 8:46 pm

Medical technology now tells us that when kids'baby teeth are kept safe,valuable cells are stored inside that can lead to possibly life-changing research work with stem cells down the road.

Remember when you were a kid and you couldn't wait until that pesky loose tooth finally wiggled itself free so that you could put it under your pillow and wait for a visit from the mysterious Tooth Fairy? A gift in exchange for an old tooth seemed like a pretty sweet deal at age 7 but now, according to medical professionals, those fallen baby teeth are the true gift; worth their weight in stem cell gold.

RELATED: 10 UNPLEASANT TRUTHS ABOUT BABY TEETHING (AND 10 THINGS MOM CAN ACTUALLY DO)

According to Small Joys, baby teeth are made nearly entirely of cells and these dental cells are going to be in big demand in the future. The reason for this is that our bodies are made completely of cells, divided in three categories of functionalities. Dental cells belong into the stem cell category and because these are caught at the early stage of development in your child's life, they just might be able to save your child's life down the road should the occasion ever arise.

For such an amazing task, you might be thinking how much is the storage going to cost at the expensive cryogenic laboratory that you're going to have to find to keep your child's baby teeth at? But no worries there because Small Joys says that according to medical technology professionals, the dental cells are already perfect preserved in their own little chambers. All you need to do is provide them with a nice, dry, safe and clean environment. This can be something as simple as a little BPA-free box with a snap lid.

NEXT:METALS IN BABY TEETH MAY HELP REVEAL THE CAUSES OF AUTISM, ADHD, STUDY SAYS

Be sure to mark the outside with the contents such as your child's complete name, the date they lost their tooth, the age they lost the tooth at, and maybe even the location of the tooth if you can. You can easily find a dental chart online. If you're feeling fancy, there are even some little cases made just for the occasion that comes with spaces for each tooth! Can't go wrong there.

In the end, hanging on to baby teeth is important to help doctors and scientists help make great strides in the world of stem cell research and breakthroughs with major diseases. Plus you've got to admit that it's also kind of cute to save for the memories, too!

Kenya Moore Of "RHOA" Shares Video Of 13-Month-Old Daughter Taking Her First Steps

Tags:health

Link:
Keeping Your Childs Baby Teeth Could Save Their Life In The Future - BabyGaga

Read More...

2020 Legislative Session A Sampling of Health Related Bills Filed – JD Supra

December 13th, 2019 8:46 pm

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

See the original post here:
2020 Legislative Session A Sampling of Health Related Bills Filed - JD Supra

Read More...

HIV Vaccine Researchers Unveil New Strategy In Fight Against HIV : Goats and Soda – NPR

December 12th, 2019 4:55 pm

An image of HIV from a scanning electron microscope. A vaccine project is in very early stages, but it's sparking interest among scientists in the field.

Ever since the AIDS epidemic erupted nearly 40 years ago, researchers have tried to make a vaccine.

The efforts typically end up like this: "Failure Of Latest HIV Vaccine Test: A 'Huge Disappointment.' "

Now researchers have come up with a new blueprint.

The method behind their potential vaccine mimics a rare process detected in the immune systems of some people with HIV a process the reduces the amount of virus in the body.

The team from Duke and Harvard behind the work, which appears this month in the journal Science, says there is still a long road ahead before an actual vaccine is ready for large-scale field trials. But scientists in the field are more optimistic than they've been for some time.

"For the first 20 years after the virus was discovered, the field tried to make a vaccine using the techniques that all the successful measles, mumps, rubella, polio vaccines had been made with in the past. And none of those worked," says Barton Haynes, director of the Duke Human Vaccine Institute and a lead author of the new research. But with a virus that's constantly mutating to evade the immune system, the antibodies generated weren't strong enough to fight it off.

But in about 20% of people who get infected with HIV, their immune systems will make special proteins called "broadly neutralizing antibodies." These antibodies live up to their name by wiping out many different strains of HIV by attacking the parts of the virus that stay constant, even as it evolves.

These proteins tend to develop several years after infection and can stop the virus from replicating for a while although they don't cure people of HIV because there's always a reservoir of the virus hiding out in cells where antibodies can't reach them.

But earlier tests in animals showed a powerful way forward: When they were infused with these antibodies before exposure to HIV, infections were prevented.

But there was a problem: The protection was short-lived.

In the new research, Haynes and his colleagues use computer modeling and lab testing on mice and monkeys to figure out how to train an immune system that's not been compromised by HIV to create these special antibodies and then continue to make new, stronger generations.

"We show a new way to design the HIV vaccine to guide the broadly neutralizing antibodies to go down paths they rarely go down on their own," Haynes says. The vaccine would also train the immune system to make these antibodies in months instead of the natural timetable of years after human exposure to the virus.

The approach looks promising to Rowena Johnston, research director at the nonprofit Foundation for AIDS Research, or amfAR, who was not involved with the study. "Nature is the best engineer when it comes to working out what our immune system should do," she says.

A vaccine based on these antibodies also has the potential to be far more effective than others in development. There currently are three HIV vaccine candidates in the final stages of human testing, and they'll be considered successful if they protect just half the exposed population from getting HIV. The benefit of this new method is that because it's introducing more powerful antibodies than the other vaccine candidates, it could lead to a vaccine that is 80-90% effective, says Dr. John Mascola, director of the Vaccine Research Center at the National Institutes of Health (NIH), who was not involved with the study.

Haynes' team is a third of the way through developing several of these antibodies, and they'll need more types to make an effective vaccine, something they say they're confident they'll be able to do.

Mascola estimates that it will take at least another five years for an HIV vaccine based on this research to get to large-scale clinical trials.

Continue reading here:
HIV Vaccine Researchers Unveil New Strategy In Fight Against HIV : Goats and Soda - NPR

Read More...

Study: Probiotic modulation of the immune system relieves hay fever symptoms – NutraIngredients.com

December 12th, 2019 4:55 pm

Griffith's research team at the Menzies Health Institute QLD carried out theanalysis, whichexamined changes in systemic and mucosal immune gene expression in a subgroup of individuals, classified as either responders or non-responders based on improvement of AR symptoms in response to the probiotic supplement.

The report notes that previous evidence suggesting that probiotics can produce clinically meaningful improvements in rhinitis symptoms is mixedand may be confounded by issues related to study design.

The assessment, published in the journalGenes,established criteria of a beneficial change in the mini-rhinoconjunctivitis quality of life questionnaire (mRQLQ).Systemic and mucosal immune gene expression was assessed using nCounter PanCancer Immune Profiling (Nanostring Technologies, Seattle, WA, USA) kit on blood samples and a nasal lysate.

There were 414 immune genes in the blood and 312 immune genes in the mucosal samples expressed above the background threshold.

Unsupervised hierarchical clustering of immune genes separated responders from non-responders in blood and mucosal samples at baseline and after supplementation, with key T-cell immune genes differentially expressed between the groups.

The report states: "Striking differences in biological processes and pathways were evident in nasal mucosa but not blood in responders compared to non-responders.

"These findings support the use of network approaches to understand probiotic-induced changes to the immune system."

Dr. Pete Smith of Queensland Allergy Services and a member of the study team said, "our study may allow us to personalise probiotic treatment for individuals with seasonal allergic rhinitis."

Dr. Nic West of Griffith University added that the results will allow researchers to conduct targeted research to find strategies people can use during the pollen season.

Source: Genes

West et al.

Digital Immune Gene Expression Profiling Discriminates Allergic Rhinitis Responders from Non-Responders to Probiotic Supplementation

DOI: 10.3390/genes10110889

Read more:
Study: Probiotic modulation of the immune system relieves hay fever symptoms - NutraIngredients.com

Read More...

This 5 spice syrup can boost your immune system this winter! – Times of India

December 12th, 2019 4:55 pm

As the chilly weather sets in, viruses and germs start operating in full swing and everybody around you seem to be catching the same flu or fever! While it is impossible to actually escape from the germs in the air (or stay away from sick people), what you can actually do is strengthen your immune system, naturally, without added supplements! Confused? Here's an easy remedy to save yourself and stay protected from diseases and enjoy the winter season.Here's whyOur immune system is charged with disease-fighting antioxidants, white blood cells, and several antibodies. However, if you have a weak immune system, you are more susceptible to catching diseases or fall sick more often. Therefore, people are often advised to include certain foods in their diet to get healthy naturally and build strong immunity. One such concoction, in particular, promises super quick results and can even act as a natural protectant against cold and fever.

How to prepare itTo make this simple winter immunity boosting syrup, you will need:

-Horseradish root (1 root)-Apple cider vinegar diluted in water (1 cup)-Turmeric (1 tablespoon)-Peppercorns (5-6 or handful)-Fennel seeds (1 tablespoon)-Clove (1 peice)-Ginger ( half a root)-Garlic (a few cloves)-Orange peel (1/2 cup)-Dried elderberries (1 tablespoon)-Honey (to soften the taste)

This immune-boosting syrup can be your go-to rescue drink whenever a cold or a flu symptom strikes you. An infusion drink of sorts, the syrup contains the goodness of herbs and potent natural medicines in diluted Apple Cider Vinegar, which again, is a super healthy drink. Together, they make an 'oxymel', a traditional honey-acid balancing mixture that can fight several germs at once.

To make this drink, first, start by straining all of the spices and herbs together in a pan filled with water (2 glasses). Allow it to simmer down completely, so as the consistency sort of thickens up. Once down, allow this prepared concoction to cool down completely, before adding it to the diluted apple cider vinegar. Mix thoroughly and allow it to settle well.

Read the rest here:
This 5 spice syrup can boost your immune system this winter! - Times of India

Read More...

The smart-dumb question, a key to writing about and understanding immunology – The Mix

December 12th, 2019 4:55 pm

The UAB freshman immunology honors seminar recently held a Q&A with Pulitzer Prize-winning newspaper reporter Matt Richtel.

The human immune system makes my head explode, Pulitzer Prize-winning journalist Matt Richtel recently told a University of Alabama at Birmingham freshman seminar on immunology. This is by far the hardest subject I have ever had to explore.

Richtel, a longtime New York Times reporter, was explaining why he wrote his general interest book An Elegant Defense The Extraordinary New Science of the Immune System, which the class was reading.

Richtels curiosity began when his boyhood buddy Jason Greenstein, the best kind of jock, got cancer in his 40s.

He had 15 pounds of cancer, went into hospice and was supposed to die, Richtel said through a video link with the UAB Honors College freshman seminar. However, when Greenstein who had nine toes in the grave got experimental immunotherapy, the cancer disappeared, though Greenstein later died. I didnt understand, Richtel said. What is this thing called the immune system, that they can tinker with to keep us alive?

Indeed, what is this thing, which is so complex and important in human health, development and disease? The UAB seminar freshmen are just beginning to scratch its surface.

In many ways, immunology is as challenging a major as neuroscience, another undergraduate major found in the UAB College of Arts and Sciences and at many other colleges.

Both the nervous system and the immune system are composed of a widespread network of organs, tissues, cells and soluble mediators that work together. Both systems interface with every organ in the body, as well as each other. Each plays critical roles in health and disease, and both require years of study for a student to grasp how the system works, and to tread a landslide of nitty-gritty mechanistic interactions that regulate normal function, or that misfire to cause disease, dysfunction and, sometimes, death.

Yet the two majors have a difference. Neuroscience is far more obvious. Each of us knows we have a brain. We daily experience five senses that report the world around us and convey pleasure or pain. Many of us have relatives or older friends who suffer the visible signs of neurodegenerative disease.

Immunology lacks this focus. Where or how does the immune system operate? What are its components? For most of us, the immune system is a vast, foggy landscape where many important things happen beneath our notice.

These differences explain, perhaps, why the number of neuroscience undergraduate majors has boomed in the past three decades, while in-depth immunology undergraduate majors still remain few. One of the few is UABs major, begun in 2017.

Three UAB faculty assert the need to revolutionize undergraduate immunology education in a Frontiers in Immunology paper.

The UAB immunology joint-health program in the UAB Department of Biology and Department of Microbiology is a four-year curriculum. After the freshman UAB honors seminar, full-semester courses include current topics in immunology, the innate immune system, the adaptive immune system, the microbial pathogen-immune system interaction, and immunologically mediated diseases.

The education is wide-ranging, and students also work in laboratories, readying themselves for careers in the health professions or research.

Immunology, by nature, is interdisciplinary, said Lou Justement, Ph.D., the teacher, along with Heather Bruns, Ph.D., of the honors seminar. Both are microbiology faculty in the UAB School of Medicine. It requires a knowledge of cellular and molecular biology, genetics, biochemistry, physiology, and anatomy. Freshmen are introduced to medically related conceptual frameworks that continue through the four-year curriculum how immunology relates to vaccines, emerging infectious diseases, autoimmunity, allergy, transplantation, cancer and immunotherapy. Students learn how the immune system is relevant to health and disease.

Richtel took a different approach. Rather than write an immunology textbook, he put faces on the role of immunology in health and disease. Parts of An Elegant Defense tell the stories of Jason, Bob, Linda and Merredith, and the burdens they faced Hodgkins lymphoma, HIV infection, rheumatoid arthritis and lupus. Richtel also relates surprising twists and turns for basic researchers who studied the immune system. Its a story, he writes at one point, that begins with a bird, a dog and a starfish.

During the video Q&A with students, Richtel wore a UAB T-shirt. Most of the UAB students asked how he reported and wrote the book. One of the hardest things to do when writing is to find your framework that will pay off the reader as you promised, he said.

And Richtel asked questions right back, offering guide stones of advice for the students:

UAB freshman Chandni Modi was one of the enthusiastic participants in the Q&A with Richtel. Afterward, the Indian Springs School graduate said, Honestly, at the beginning of my high school senior year, UAB wasnt one of my top choices. However, after I started comparing my options, UAB was the only school that offered immunology as a major, and UAB offers so many ways to get involved in research.

Also, she said, I appreciated how diverse the university students and faculty are.

Go here to read the rest:
The smart-dumb question, a key to writing about and understanding immunology - The Mix

Read More...

Seasonally Decreased Immune Function Around the Holidays – Matthews Beacon

December 12th, 2019 4:55 pm

The human immune system is highly complex and multi-faceted. Seemingly an infinite number of things can affect our internal landscape and alter how our immune system defenses respond to and fight foreign invaders to keep us healthy. The misconception a lot of people have is thinking that we want a super active immune system that is like Rambo, an ultimate killing machine! Really what we want is a balanced immune system, that neither swings into hyperactivity nor falls into decreased function. If our immune system functions too high, we end up with autoimmune disorders this is when the immune system attacks our bodys cells, not just foreign invaders, if it is not functioning as it should, when exposed to germs we get sick and have to fight off an illness.

Did you know that just the time of year can affect our immune system function? Just the fact that the daylight does not last as long can cause our immune system to be less responsive. Shorter days and colder weather cause people to stay inside more, reducing the amount of natural vitamin D they make, which is a key immune system booster. An alternative for the individual not wanting to go outside is supplementing Vitamin D into their diet.

Read more here:
Seasonally Decreased Immune Function Around the Holidays - Matthews Beacon

Read More...

By turning stem cells into brain cells, Aspen Neuroscience hopes to rewind the progress of Parkinson’s disease – FierceBiotech

December 12th, 2019 4:55 pm

The idea of a cell therapy for Parkinsons disease starts out simple: Symptoms of the progressive disease are largely driven by the deaths of dopamine-producing neurons found deep within the brain. With lower levels of the neurotransmitter come the characteristic tremors, rigidity and slow movements.

By replacing those lost nerve cells with new dopamine producers, researchers hope to renew the brains connection to the bodys muscles and improve a persons overall motor function.

But in the brain, everything becomes more complicated. On top of the risk of immune system rejection that comes with any kind of living tissue transplant, its important to make sure the implanted cells function correctly and do not pick up any dangerous genetic mutations as they grow.

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Now, a new company, Aspen Neuroscience, aims to tackle both obstacles at once.

First, the startup hopes to avoid any harmful immune reactions by using a patients own cells as a starting point. Then, Aspen plans to implement a rigorous quality control program employing whole genome sequencing and artificial intelligence to make sure the cells stay in line as theyre processed and readied for the procedure.

And to do it, the San Diego-based company is starting out with $6.5 million in seed money plus an impressive roster of names.

They are led by neurology researcher Howard Federoff, previously vice chancellor for health affairs and CEO of the University of California, Irvine health system as well as the executive dean of medicine at Georgetown University. Hes joined by Aspen co-founder and stem cell scientist Jeanne Loring, founding director and professor emeritus of the Center for Regenerative Medicine at the Scripps Research Institute.

Meanwhile, the seed round was led by Domain Associates and Axon Ventures with additional backing from Alexandria Venture Investments, Arch Venture Partners, OrbiMed and Section 32.

Aspen looks to combine its expertise in stem cell biology, genomics and neurology to offer the first autologous cell therapy for Parkinsons diseasewhile others in the space have pursued allogeneic routes, or therapies derived from donors other than the patient.

The process starts with a culture of the patients skin cells, which are then genetically induced to become pluripotent stem cellsor cells capable of differentiating into any other cell type in the body. These are then chemically nudged further to transform into precursor versions of the dopamine-producing neurons, which are typically found in the midbrain and regions responsible for the movement of limbs.

We can say without any equivocation that we can produce the population of cells necessary to transplant, and in a short enough period of time to have a potential beneficial impact on the evolution of the disease, said Federoff, who has also served as chair of the NIHs Recombinant DNA Advisory Committee and helped lead the U.S. Parkinsons Disease Gene Therapy Study Group.

We envisage that this will set back the clock on patients who have Parkinsons, unlike any other therapy that we know of, he told FierceMedTech in an interview.

The number of cells needed would be much smaller compared to other cell therapies and cancer treatments. The healthy human brain contains only about 200,000 dopamine-producing nerve cells, split between its two hemispheres, while patients with Parkinsons disease have lost about 50% or more of those neurons.

Aspen aims to evaluate two doses: one that aims to replace about 60% to 65% of a persons normal cell complement and another larger treatment, Federoff said.

Those smaller doses, as well as starting with a patients donor cells, help make the treatment safer to produce by requiring fewer steps. Each cycle of cell division and multiplication to increase their numbers carries the risk of introducing genetic mutations.

As the cells are grown, they are consistently evaluated with data-driven techniques pioneered by Lorings laboratory. Using whole genome RNA sequencing, Aspen will match the cells up at every stage with a genetic barcode taken from each patient at the start. This will allow them to look for changes, duplications or deletions in the pluripotent stem cell genome.

If the cells harbor mutations that are cancer drivers, we don't want to put those into people, Loring said. The only way is to check the sequencing before we transplant them.

The cells used in the transplant procedure arent fully grown; as neuron progenitors, they mimic the development steps seen in the brain of a growing fetus after theyre placed in the body as they wire themselves up to other neural structures and begin to form new networks of their own.

We anticipate that they will manufacture and release dopamine in a manner that is consistent with synaptic neurotransmission and the process of communicating from cell-to-cell, said Federoff. They will take up dopamine from synapses when it has done its business, bring it back into the cell, and prepare it for another synaptic release.

These are not just dopamine pumps, theyre real neurons, added Loring. They will genuinely replace the cells that have been lost in every way.

Aspen plans to pursue two courses of therapy, for the two major types of Parkinsons disease. Their lead candidate is for idiopathic, or sporadic Parkinsons, while their second is a CRISPR-edited version of the therapy designed to address one of the diseases most common genetic mutations, linked to about 5% of cases.

This would not only aim to restart dopamine production in this orphan indication, but also restore the damaged enzyme GBA, which is seen as an underlying cause. Federoff and Loring expect their sequencing-based quality check system will also help catch any off-target edits linked to the use of CRISPR-Cas9.

The company has yet to secure permission from the FDA to officially launch clinical trials, but the agency has signed off on Aspens plans to prepare a trial-ready cohort of Parkinsons disease patients in the meantime. This would include the initial stages of recruitment and testing, including the selection of patients capable of having their skin cells made into pluripotent stem cells.

After it receives its go-ahead from the FDA, Aspen plans to hit the ground running,enrolling at least 176 participants in a phase 1/2 study that includes a randomized stage to determine clinical benefits.

Read more:
By turning stem cells into brain cells, Aspen Neuroscience hopes to rewind the progress of Parkinson's disease - FierceBiotech

Read More...

Father’s X chromosome may yield clues to higher rates of autoimmune disease in women – Newswise

December 12th, 2019 4:55 pm

MEDIA CONTACT

Available for logged-in reporters only

By Sarah C.P. Williams

Newswise UCLA scientists have discovered one reason why autoimmune diseases are more prevalent in women than in men. While males inherit their mothers X chromosome and fathers Y chromosome, females inherit X chromosomes from both parents. New research, which shows differences in how each of those X chromosomes is regulated, suggests that the X chromosome that females get from their father may help to explain their more active immune system.

Its been known for many years that women are more susceptible to autoimmune diseases than men are, said lead study author Dr. Rhonda Voskuhl, a UCLA professor of neurology and director of the UCLA Multiple Sclerosis Program who also holds the Jack H. Skirball Chair in Multiple Sclerosis Research. Figuring out why can help us develop new drugs to treat these autoimmune diseases.

Autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis, are conditions that affect the bodys ability to fight viruses, bacteria and infections. The problem causes a persons immune cells to attack the body instead.

Women generally have stronger immune responses than men, with more robust responses to some vaccinations and infections. However, this heightened immune system also makes women three times more likely than men to develop multiple sclerosis, nine times more likely to develop lupus ,and more prone to a host of other autoimmune diseases, Voskuhl said. The effect of sex hormones testosterone and estrogen in these differences has been well-studied, but the role of sex chromosomes has been less clear.

In thenew work, published in Proceedings of the National Academy of Sciences, Voskuhl and her colleagues focused on differences between the X chromosomes inherited from each parent. They first analyzed expression levels of genes in mice with the male (XY) and female (XX) chromosome set. They identified a handful of immune system-related genes on the X chromosome that are expressed less producing fewer corresponding molecules in the immune cells of female mice.

To further study these differences, the Voskuhl team next compared mice that had just one X chromosome either a maternal or paternal X chromosome. They determined levels of methylation the addition of methyl chemical groups to DNA in the X chromosomes. Methylation is known to turn down, or block, the expression of genes. And while the methyl groups arent part of the DNA sequence itself, patterns of methylation can be passed from parent to child. The researchers discovered that there was more methylation on paternal than on maternal X chromosomes. Finally, they confirmed that several genes on the X chromosome were expressed less when the X chromosome was of paternal as compared to maternal origin.

What were talking about here is not mutations that affect gene sequences, but instead signals that affect how the same sequence of genes are differentially expressed in females versus males. These differences would be missed in traditional genetic studies, Voskuhl said.

The findings suggest that the X chromosomes packaged into sperm and passed from father to daughter may have higher levels of methylation than the X chromosomes passed along in eggs from a mother to her offspring. This methylation dampens the expression of some immune system genes in females, making their immune activity different from males.

If you can find regulators of methylation that target these differences, you might be able to reduce the immune responses of females to treat autoimmune diseases, Voskuhl said. Going forward, when one considers sex as a biologic variable in diseases, it can lead to new treatment strategies.

More work is needed to determine whether the same is seen in humans as mice and whether the methylation differences lead to measurable differences in autoimmune disease risk. Voskuhl said the new research is an important step toward better understanding sex differences in disease, a goal that the National Institutes of Health underscored the importance of in 2016 when it mandated that researchers consider sex as a biological variable in their grant applications.

The first authors of the study are graduate student Lisa Golden and associate researcher Yuichiro Itoh, both of UCLA.

Study funders include the National Institutes of Health, the Conrad N. Hilton Foundation, the Tom Sherak MS Hope Foundation and the Rhoda Goetz Foundation for Multiple Sclerosis.

SEE ORIGINAL STUDY

See the original post here:
Father's X chromosome may yield clues to higher rates of autoimmune disease in women - Newswise

Read More...

Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of…

December 12th, 2019 4:54 pm

The new field of immunometabolism is the study of how metabolic pathways control immune cell differentiation and function

Rheos Medicines, a biopharmaceutical company harnessing insights in immunometabolism to create a new class of therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer, today announced the online publication of a perspective in Cell Metabolism that highlights the rationale and potential of employing principles of immunometabolism to discover and develop novel medicines. The article, entitled The Untapped Opportunity and Challenge of Immunometabolism: A New Paradigm for Drug Discovery, was published online today in Cell Metabolism (DOI: 10.1016/j.cmet.2019.11.014).

Immune cells modulate their energy requirements in response to changes in their environment, which include interactions with pathogens, tumor cells, other immune system cells and molecules such as growth factors and antibodies. The metabolic programs that are induced or inhibited as immune cells respond to such stimuli can drive immune cell activation, differentiation, or suppression. Understanding the mechanisms through which metabolism can dictate the function or fate of immune cells is a new platform for target and biomarker discovery with a goal of identifying new medicines with potential to selectively tune the immune system to amplify or dampen its response. The perspective reviewed the underlying biology of immunometabolism and the new tools to discover and develop novel therapeutics based on this paradigm.

"To exploit this new field of immunometabolism, we have developed and industrialized a platform that comprehensively elucidates the metabolic pathways and targets with potential to control immune cell fate or function, as well as their associated metabolite biomarkers," said Laurence Turka, M.D., Chief Scientific Officer and co-founder of Rheos. "Our approach employs a proprietary integration of metabolomic, transcriptomic, and other data to generate immunometabolism network maps (imMAPs) that characterize immune cell activation and differentiation through a metabolic lens. Our imMAPs have potential to tap currently undiscovered or poorly understood biology and enable development of new therapeutics for a wide range of diseases including autoimmunity and cancer."

Barbara Fox, Ph.D., Chief Executive Officer of Rheos, added, "Immunometabolism has the potential to be the next frontier in drug discovery. Our pioneering product engine has the breadth and power to identify novel metabolic targets across a diverse set of pathways, better understand the metabolic impact of existing therapies and bring the benefits of personalized medicine to autoimmunity. Based on our work to-date, we have initiated drug discovery efforts in a number of programs and we look forward to providing further updates as we continue to make progress."

About Rheos Medicines

Rheos Medicines is a biopharmaceutical company harnessing insights in immunometabolism to develop novel therapeutics for patients with severe autoimmune disorders, inflammatory diseases and cancer. Our approach targets the underlying intracellular metabolism of immune cells and has the potential to unlock a new frontier in drug discovery for immune-mediated disease. Through a proprietary platform and product engine that integrates multiple "omic" datasets, we systematically define the biologic links between immune cell metabolism and function and simultaneously identify new drug targets and biomarkers of disease to bring precision to the treatment of immune-mediated diseases. We have assembled leading scientists whose discoveries opened the field of immunometabolism, clinicians with a deep understanding of immune-mediated diseases, and an experienced biotech leadership team. Rheos was founded by Third Rock Ventures and is located in Cambridge, MA. For more information, please visit http://www.rheosrx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005550/en/

Contacts

INVESTORS & MEDIA: Investors: Gad SofferChief Operating Officergsoffer@rheosrx.com 650-477-8183

John Grimaldi, Burns McClellanjgrimaldi@burnsmc.com 212-213-0006 x362

Media: Ryo Imai / Robert Flamm, Ph.D., Burns McClellanrimai@burnsmc.com / rflamm@burnsmc.com 212-213-0006 x315 / 364

Read the original here:
Rheos Medicines Announces Publication of Perspective in Cell Metabolism Highlighting the Rationale and Potential of Employing Principles of...

Read More...

BioAegis Therapeutics Announces Publication: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe…

December 12th, 2019 4:54 pm

MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of new research findings with recombinant human plasma gelsolin in influenza. The research demonstrates that recombinant human plasma gelsolin therapy dramatically improves survival in a highly lethal influenza animal model.

Access Publication https://f1000research.com/articles/8-1860/v1

Findings Indicate That Plasma Gelsolin Supplementation Can Improve Influenza Outcomes

Seasonal influenza continues to be a cause of substantial morbidity and mortality. The US Center for Disease Control and Prevention (CDC) documented that seasonal influenza was responsible for close to 57,000 deaths during the 2018-2019 season. There is also concern that new strains could cause high death rates similar to past pandemics.

Studies conducted in collaboration with investigators at the Harvard T.H. Chan School of Public Health demonstrated clinical improvement in mice infected with lethal doses of influenza when administering gelsolin after a clinically relevant delay. The current FDA-approved antivirals target the flu virus, but do not address the severe later stage morbidity and mortality that that are the focus of plasma gelsolin (rhu-pGSN) therapy. Currently, resistance is also developing against the antivirals, which is why host-directed therapies are increasingly being sought for development.

Susan Levinson, PhD, Chief Executive Officer of BioAegis Therapeutics stated, Weve previously studied plasma gelsolin against multiple types of drug-sensitive and drug-resistant bacteria and this new data has demonstrated efficacy in influenza, a key viral pandemic threat. Each time we extend our studies with plasma gelsolin, we become even more persuaded of its potential to address serious medical needs where current therapy fails.

Research Presented at Recent Government Influenza Thought Leader Conference

Last month BioAegis was invited to participate in a workshop on REducing Pathogens After Influenza immune Response (repAIR) organized by the US Department of Health and Human Services BARDA (Biomedical Advanced Research and Development Authority), NIH (National Institute of Health) and ASPR (Assistant Secretary for Preparedness and Response). The conferences mission was to, Bring together thought leaders from multiple disciplines in medical research and clinical sciences who are interested in the study of host-based therapeutic interventions to provide more effective treatment of patients hospitalized with severe influenza.

Need for Host-directed Therapeutics Sought by Department of Health and Human Services

According to the Department of Health and Human Services, In the event of an influenza pandemic, or the annual seasonal epidemic, a therapeutic approved to treat individuals with late stage influenza disease could save tens to hundreds of thousands of lives. In addition, there is potential broad applicability of a host-based treatment to other infectious diseases.

Mark Dinubile, MD, Chief Medical Officer of BioAegis Therapeutics presented Plasma Gelsolin As Immunotherapeutic in Pneumonia including studies conducted by BioAegis Chief Scientific Advisor, Dr. Lester Kobzik at the Harvard TH Chan School of Public Health. The presentation highlighted the key finding -- plasma gelsolins unique ability to treat both viral and bacterial infections a pathogen agnostic approach.

While in Washington, D.C., Dr. Susan Levinson, CEO of BioAegis also presented this data at BARDAs TechWatch. BARDA has invested in many infectious threat programs, however, the space where pGSN is effective represents a gap in their portfolio.

About BioAegis Therapeutics

BioAegis Therapeutics Inc. is a clinical stage, private company whose mission is to exploit a key component of the bodys innate immune system to prevent adverse outcomes of diseases driven by inflammation and infection. BioAegis platform of opportunities exploits the multifunctional role of plasma gelsolin, a highly conserved, endogenous human protein.

Gelsolin has the potential to fill a major gap in the current treatment of inflammatory disease by controlling excess inflammation without suppressing the immune response to threats. In addition, recent findings demonstrate gelsolins unique pathogen agnostic approach its ability to treat both viral and bacterial infections.

In 2019, BioAegis successfully completed a Phase 1b/2a Community-Acquired Pneumonia clinical trial. BioAegis now is fundraising for its phase 2b trial in severe pneumonia. This study is designed to demonstrate gelsolin repletion reduces morbidity and mortality in severe pneumonia patients, a group that is at high risk for poor outcomes due to injurious inflammation.

This press release contains express or implied forward-looking statements, which are based on current expectations of management. These statements relate to, among other things, our expectations regarding managements plans, objectives, and strategies. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.

For further information:

Steven Cordovano, 203-952-6373Email: scordovano@bioaegistx.comwww.bioaegistx.com

Visit link:
BioAegis Therapeutics Announces Publication: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe...

Read More...

Depletion of microbiome-derived molecules in the host using Clostridium genetics – Science Magazine

December 12th, 2019 4:54 pm

Chun-Jun Guo

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.Jill Roberts Institute for Research in Inflammatory Bowel Disease, Department of Medicine, Weill Cornell Medicine, NY 10021, USA.

Breanna M. Allen

Graduate Program in Biomedical Sciences, Departments of Otolaryngology and Microbiology and Immunology, Helen Diller Family Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA 94143, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Kamir J. Hiam

Graduate Program in Biomedical Sciences, Departments of Otolaryngology and Microbiology and Immunology, Helen Diller Family Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA 94143, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Dylan Dodd

Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA.Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.

Will Van Treuren

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Steven Higginbottom

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Kazuki Nagashima

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.

Curt R. Fischer

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Justin L. Sonnenburg

Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Matthew H. Spitzer

Graduate Program in Biomedical Sciences, Departments of Otolaryngology and Microbiology and Immunology, Helen Diller Family Comprehensive Cancer Center, Parker Institute for Cancer Immunotherapy, University of California, San Francisco, San Francisco, CA 94143, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

Michael A. Fischbach

Department of Bioengineering and ChEM-H, Stanford University, Stanford, CA 94305, USA.Chan Zuckerberg Biohub, San Francisco, CA 94158, USA.

See the article here:
Depletion of microbiome-derived molecules in the host using Clostridium genetics - Science Magazine

Read More...

Using droplet digital PCR to monitor the safety of CAR T cells – Drug Target Review

December 12th, 2019 4:54 pm

CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR (ddPCR) is more than a match for this technique.

CHIMERIC antigen receptor (CAR) T cells, first tested in cancer patients less than a decade ago,1 represent the latest generation of adoptive cell therapy and the most personalised approach to date. CAR T-cell therapy is a method of supercharging a patients immune system to fight their cancer and it involves three stages. First, T cells are isolated from a patients blood; then, using either viral vectors, transposon systems or mRNA transduction,2 T cells are genetically modified to express the CAR protein on their surface. Finally, the T cells are amplified in culture and infused back into the patient where they attack the cancer cells.

CAR T-cell therapy is rapidly gaining popularity as a specific method for treating cancer. According to clinicaltrials.gov, there are currently over 300 active or recruiting CAR T-cell therapy trials underway,3 mostly taking place in the US and China.4 According to one forecast, the global market for CAR T-cell therapies is expected to grow to $8 billion by 2028.5 However, since CAR T cells are a living therapy, as opposed to a synthetic drug, the process of preparing them to assure safety and effectiveness in patients is complex.

See the original post here:
Using droplet digital PCR to monitor the safety of CAR T cells - Drug Target Review

Read More...

Trending News: Hypothyroidism Linked to Increased All-Cause Mortality in Patients 60 Years or Older – Pharmacy Times

December 12th, 2019 4:54 pm

Trending News: Hypothyroidism Linked to Increased All-Cause Mortality in Patients 60 Years or Older

Two migraine prevention agents, cinnarizine and sodium valproate, were shown to be safe and effective in reducing incidence and severity of migraine within children and adolescents, according to the American Journal of Managed Care. In a randomized double-blind placebo-controlled trial including 149 Iranian pediatric and adolescent patients, patients were randomly assigned at 1:1:1 ratio to receive cinnarizine, sodium valproate, or placebo. Compared with placebo, the 2 preventive agents exhibited significant reductions in migraine incidence and severity, warranting further analyses into their efficacy among the global population.

New research indicates that hypothyroidism could be linked to increased all-cause mortality in patients aged 60 years and older, according to MD Magazine. An international team of researchers conducted a systematic review and meta-analysis of PubMed, Embase, Cochrane Library, Scopus, and Web of Science databases. Their findings indicate that patients aged 60 years or older with subclinical hypothyroidism (those who have a milder thyroid dysfunction) may not benefit from a treatment with synthetic thyroid hormone.

Read more from the original source:
Trending News: Hypothyroidism Linked to Increased All-Cause Mortality in Patients 60 Years or Older - Pharmacy Times

Read More...

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease – P&T…

December 12th, 2019 4:53 pm

SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round led by Domain Associates and Axon Ventures and including Alexandria Venture Investments,Arch Venture Partners,OrbiMedand Section 32 to develop the first autologous cell therapies for Parkinson's disease. Aspen's proprietary approach was developed by the company's co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Loring's lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinson's disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.

Parkinson's disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. The company's research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinson's disease.

As an autologous cell therapy for Parkinson's disease, Aspen's treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinson's disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinson's disease.

Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinson's Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.

Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the world's rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.

Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.

"Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson's disease," said Dr. Federoff. "We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist."

Aspen's lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA). Aspen leverages proprietary machine-learning tools and artificial intelligence to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.

"Aspen's financial backing, combined with its experienced and proven leadership team, positions it well for future success," said Kim P. Kamdar, Ph.D., Partner at Domain Associates, one of Aspen's seed investors. "Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in people's lives. We clearly see Aspen as fitting into that category, as it is the only company using a patient's own cells for replacement therapy in Parkinson's disease."

About Aspen Neuroscience

Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visithttp://www.aspenneuroscience.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aspen-neuroscience-launches-with-6-5-million-seed-funding-to-advance-first-of-its-kind-personalized-cell-therapy-for-parkinsons-disease-300973830.html

SOURCE Aspen Neuroscience

More:
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - P&T...

Read More...

New Mechanism of Bone Maintenance and Repair Discovered – Technology Networks

December 12th, 2019 4:53 pm

Led by researchers at Baylor College of Medicine, a study published in the journal Cell Stem Cell reveals a new mechanism that contributes to adult bone maintenance and repair and opens the possibility of developing therapeutic strategies for improving bone healing.

Adult bone repair relies on the activation of bone stem cells, which still remain poorly characterized, said corresponding author Dr. Dongsu Park, assistant professor of molecular and human genetics and of pathology and immunology at Baylor. Bone stem cells have been found both in the bone marrow inside the bone and also in the periosteum the outer layer of tissue that envelopes the bone. Previous studies have shown that these two populations of stem cells, although they share many characteristics, also have unique functions and specific regulatory mechanisms.

Of the two, periosteum stem cells are the least understood. It is known that they comprise a heterogeneous population of cells that can contribute to bone thickness, shaping and fracture repair, but scientists had not been able to distinguish between different subtypes of bone stem cells to study how their different functions are regulated.

In the current study, Park and his colleagues developed a method to identify different subpopulations of periosteum stem cells, define their contribution to bone fracture repair in live mouse models and identify specific factors that regulate their migration and proliferation under physiological conditions.

Periosteal stem cells are major contributors to bone healing

The researchers discovered specific markers for periosteum stem cells in mouse models. The markers identified a distinct subset of stem cells that contributes to life-long adult bone regeneration.

We also found that periosteum stem cells respond to mechanical injury by engaging in bone healing, Park said. They are important for healing bone fractures in the adult mice and, interestingly, their contribution to bone regeneration is higher than that of bone marrow stem cells.

In addition, the researchers found that periosteal stem cells also respond to inflammatory molecules called chemokines, which are usually produced during bone injury. In particular, they responded to chemokine CCL5.

Periosteal stem cells have receptors molecules on their cell surface that bind to CCL5, which sends a signal to the cells to migrate toward the injured bone and repair it. Deleting the CCL5 gene in mouse models resulted in marked defects in bone repair or delayed healing. When the researchers supplied CCL5 to CCL5-deficient mice, bone healing was accelerated.

The findings suggested potential therapeutic applications. For instance, in individuals with diabetes or osteoporosis in which bone healing is slow and may lead to other complications resulting from limited mobility, accelerating bone healing may reduce hospital stay and improve prognosis.

Our findings contribute to a better understanding of how adult bones heal. We think this is one of the first studies to show that bone stem cells are heterogeneous and that different subtypes have unique properties regulated by specific mechanisms, Park said. We have identified markers that enable us to tell bone stem cell subtypes apart and studied what each subtype contributes to bone health. Understanding how bone stem cell functions are regulated offers the possibility to develop novel therapeutic strategies to treat adult bone injuries.

Reference

Ortinau et al. (2019) Identification of Functionally Distinct Mx1+SMA+ Periosteal Skeletal Stem Cells. Cell Stem Cell. DOI: https://doi.org/10.1016/j.stem.2019.11.003

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Continued here:
New Mechanism of Bone Maintenance and Repair Discovered - Technology Networks

Read More...

Page 772«..1020..771772773774..780790..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick